Abstract
The α4β2 nicotinic acetylcholine receptors (nAChRs), a major subtype in the brain, have been shown to be modulated by chronic treatment with nicotine. In this study, the regulation of recombinant human α4β2 nAChR subtype by (−)-nicotine and other cholinergic channel modulators was studied using human embryonic kidney 293 cells stably expressing this subunit combination. The treatment of transfected cells with (−)-nicotine and other activator ligands, including (−)-cytisine, 1,1-dimethyl-4-phenylpiperazinium, (S)-3-methyl-5-(1-methyl-2-pyrrolidinyl)isoxazole, and (±)-epibatidine, resulted in concentration-dependent increases in the levels of α4β2 nAChRs. The increase in [3H]cytisine binding sites was initiated by low concentrations of (−)-nicotine (<100 nm); was maximal at 10 μm (15-fold), rapid (t 0.5 = 4.0 ± 0.5 hr), and totally reversible (t 0.5 = 11.7 ± 0.1 hr); and occurred with no change in ligand binding affinity. Antagonists, including dihydro-β-erythroidine, d-tubocurarine, and methyllycaconitine, also elicited significant increases in receptor levels. A good correlation was observed between theKi values for binding inhibition and the EC50 values for receptor up-regulation. Treatment of cells with mecamy-lamine, a noncompetitive antagonist, did not change receptor levels or alter (−)-nicotine-evoked up-regulation. (−)-Nicotine-evoked up-regulation was blocked by cycloheximide, suggesting a role for protein synthesis. Treatment of cells with (−)-nicotine or dihydro-β-erythroidine differentially modulated the efficacy of acetylcholine to activate cation efflux. Both 6-β-[β′(piperidino)propionyl]forskolin and phorbol-12-myristate-13-acetate increased [3H]cytisine binding sites and nAChR function and enhanced the effects of chronic (−)-nicotine treatment in a synergistic manner. These results collectively demonstrate that human α4β2 nAChRs can be differentially up-regulated by chronic treatment with nAChR ligands and activation of protein kinase A- and protein kinase C-dependent mechanisms.
Footnotes
- Received October 22, 1996.
- Accepted May 20, 1997.
-
Send reprint requests to: Murali Gopalakrishnan, Ph.D., Neuroscience Research (D-47C; Bldg. AP10LL), Pharmaceutical Products Division, Abbott Laboratories, 100 Abbott Park Road, Abbott Park, IL 60064-3500. E-mail:murali.gopalakrishnan{at}abbott.com
- The American Society for Pharmacology and Experimental Therapeutics
MolPharm articles become freely available 12 months after publication, and remain freely available for 5 years.Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page.
|